Rex Capital Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
EP
Rex Capital Advisors's ARKG Position: Q4 2021 in Review
Rex Capital Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 7,142 shares — an estimated $534K sold.
Rex Capital Advisors first reported a position in ARKG in Q1 2021 and held it in 3 quarters. The position peaked at $661K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.
- Rex Capital Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
- Rex Capital Advisors sold 7,142 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $534K.
- Rex Capital Advisors first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 3 quarters.
- Rex Capital Advisors's ARK Genomic Revolution ETF position peaked at $661K in Q2 2021.
- 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.
Based on Rex Capital Advisors's 13F filing for Q4 2021, filed 11 Feb 2022.